Erythropoietin (EPO) vs PT-141
Extensively Studied vs FDA Approved
monitor Mechanism-based · 60% Both Erythropoietin (EPO) and PT-141 can raise blood pressure. Monitor BP regularly and consider adding cardiovascular support (cardarine, telmisartan, or similar).
Molecular Data
Erythropoietin (EPO) PT-141
Weight 30,400 Da —
Half-life 4-12 hours (IV), ~25 hours (SubQ) ~2.7 hours
Chain 165 amino acids —
Type Glycoprotein hormone Melanocortin receptor agonist
Key Benefits
Erythropoietin (EPO)
01 Stimulates red blood cell production
02 Increases oxygen-carrying capacity
03 FDA-approved for anemia treatment
04 Improves endurance capacity
05 Supports patients with chronic kidney disease
06 Helps chemotherapy-induced anemia
07 Well-characterized mechanism of action
08 Extensively studied safety profile
PT-141
01 FDA-approved pharmaceutical route
02 Predictable absorption profile
03 Effective for both male and female sexual dysfunction
04 Works within 45 minutes
05 Effective in PDE5 inhibitor-resistant cases
06 Central mechanism (not dependent on blood flow)
Dosing Protocols
Erythropoietin (EPO)
50-300 IU/kg based on medical indication / 1-3 times weekly depending on response
CKD Anemia (medical) 50-100 IU/kg 3x weekly
Chemotherapy Anemia (medical) 150-300 IU/kg 3x weekly
Maintenance (medical) Individualized 1-3x weekly
PT-141
Women: 1.75mg (FDA-approved); Men: 1-2mg; Start 0.5mg test dose for tolerance / As needed before sexual activity; max 1 dose per 24 hours
Female HSDD (FDA-approved) 1.75mg As needed, max 1 dose/24hr
Male Erectile Dysfunction 1-2mg As needed, 45-60min before activity
Female Arousal Disorder 0.75-1.25mg As needed, max 1 dose/24hr
Low Starting Dose 0.5mg Test dose for tolerance assessment
Side Effects
Erythropoietin (EPO)
Injection site reactions
Headache
Hypertension
Joint pain
Flu-like symptoms
PT-141
Nausea (40%)
Flushing (20%)
Headache (11%)
Injection site reactions
Contraindications
Uncontrolled hypertension
Pure red cell aplasia history
Hemoglobin >12 g/dL (increased cardiovascular risk)
Active malignancy (relative contraindication)
Uncontrolled hypertension
Cardiovascular disease
Use of nitrate medications
Pregnancy or breastfeeding
Research Evidence
Erythropoietin (EPO) PT-141
Status Extensively Studied FDA Approved
References 4 studies 4 studies
Latest — 2022
FDA Approved Yes Yes
This comparison is for educational and research purposes only. Consult a healthcare professional before use.